Pfizer Out-Licenses its Pan-HER Inhibitor Neratinib to Puma Biotechnology
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 10 (Table of Contents)
Published: 31 Oct-2011
DOI: 10.3833/pdr.v2011.i10.1591 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Puma Biotechnology, the new start-up of the founder of Cougar Biotechnology, has in-licensed worldwide development and commercialisation rights to Pfizer’s investigational pan-HER inhibitor neratinib following a pipeline review at the big pharma company...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS